Back to top
more

Galapagos (GLPG)

(Delayed Data from NSDQ)

$28.55 USD

28.55
75,533

-0.22 (-0.76%)

Updated May 10, 2024 03:59 PM ET

After-Market: $28.56 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead & Galapagos Announce Positive Data on UC Candidate

Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.

Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study

Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.

Galapagos Begins Dosing With GLPG3970 in Psoriasis Study

Galapagos (GLPG) doses the first patient in an early-stage study on its Toledo compound GLPG3970 for treating psoriasis. The same is also being studied for ulcerative colitis and rheumatoid arthritis.

Gilead & Galapagos' RA Drug Receives Approval in Europe

Gilead (GILD) and partner Galapagos win approval for their rheumatoid arthritis (RA) drug in Europe.

Galapagos Gets First Commercial Drug With Jyseleca Approval

Galapagos (GLPG) and Gilead announce approval of Jyseleca in Europe as a treatment for rheumatoid arthritis patients.

Gilead's Rheumatoid Arthritis Drug Gets Approval in Japan

Gilead's (GILD) rheumatoid arthritis drug, Jyseleca, wins approval in Japan.

New Strong Sell Stocks for September 25th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Galapagos (GLPG) Surges: Stock Moves 8.8% Higher

Galapagos (GLPG) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Company News for Aug 20, 2020

Companies In The News Are: MNTA, JNJ, TGT, REGN, GLPG, GILD.

Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Gilead (GILD) Gets CRL From FDA for Rheumatoid Arthritis Drug

Gilead (GILD) suffers a setback as the FDA issues a CRL for its rheumatoid arthritis drug.

Gilead (GILD) Misses on Q2 Earnings & Sales, Ups '20 Guidance

Gilead (GILD) reports weaker-than-expected results for the second quarter but ups annual guidance.

Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More

The biotech sector remains in focus with earnings, regulatory and other pipeline updates.

Gilead's Rating Upgraded on Potential Coronavirus Drug Sales

Gilead (GILD) rides high on potential sales from its experimental coronavirus treatment, remdesivir, and collaboration with Arcus.

Gilead (GILD) Gains 13% YTD on Coronavirus Drug Development

Gilead's experimental coronavirus drug, remdesivir, shows promise. The stock has been in news since the onset of the year on updates from the same.

Gilead, Galapagos Announce Positive Data on Inflammatory Drug

Gilead (GILD) and Galapagos announce positive data on filgotinib for the treatment of ulcerative colitis.

Why Galapagos (GLPG) Might Surprise This Earnings Season

Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.

Vertex (VRTX) Hits 52-Week High, Can the Run Continue?

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Gilead (GILD) Partners With Eisai for RA Candidate in Japan

Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.

Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib

Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.

Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat

Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.

Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.

Gilead-Galapagos Report Efficacy & Safety Results on RA Drug

Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.

Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan

Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.